LMR Partners’s Quince Therapeutics QNCX Stock Holding History

LMR Partners’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-143	Closed	-$360K	–	1333
2021 Q4	$360K	Buy	+143	New	+$873K	﹤0.01%	988

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's QNCX Position: Q1 2022 in Review

LMR Partners sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 143 shares — an estimated $360K sold.

LMR Partners first reported a position in QNCX in Q4 2021 and held it in 1 quarter. The position peaked at $360K in Q4 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

LMR Partners reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
LMR Partners sold 143 Quince Therapeutics shares in Q1 2022, an estimated $360K.
LMR Partners first reported a position in Quince Therapeutics in Q4 2021 and held it in 1 quarter.
LMR Partners's Quince Therapeutics position peaked at $360K in Q4 2021.
85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on LMR Partners's 13F filing for Q1 2022, filed 16 May 2022.